Pharmacokinetics and pharmaco dynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3630-3633

  Trampuz, Andrej ^a   Laifer, Gerd ^a   Wenk, Markus ^a   Rajacic, Zarko ^a   Zimmerli, Werner ^a  

^a Medical University Clinic   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BLISTER; BULLOUS SKIN DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; GRANULOCYTE; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; CLINICAL TRIAL; DRUG EFFECT; ENTERIC COATED TABLET; EXUDATE; HALF LIFE TIME; METABOLISM; MICROBIOLOGY; SERUM BACTERICIDAL ACTIVITY; SKIN;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BLOOD BACTERICIDAL ACTIVITY; EXUDATES AND TRANSUDATES; FLUOROQUINOLONES; GRANULOCYTES; HALF-LIFE; SKIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TABLETS, ENTERIC-COATED;

EID: 0036827127     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3630-3633.2002     Document Type: Article

References (22)

1. Blondeau, J. M. 1999. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J. Antimicrob. Chemother. 43(Suppl. B):1-11.
2. Catchpole, C., J. M. Andrews, J. Woodcock, and R. Wise. 1994. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v, and 750 mg p.o. J. Antimicrob. Chemother. 33:103-110.
3. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
4. Gaijar, D. A., F. P. LaCreta, H. D. Uderman, G. D. Kollia, G. Duncan, M. J. Birkhofer, and D. M. Grasela. 2000. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 20:49S-58S.
5. Grasela, D. M. 2000. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin. Infect. Dis. 31(Suppl. 2):S51-S58.
6. Hoellman, D. B., G. Lin, M. R. Jacobs, and P. C. Appelbaum. 1999. Antipneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J. Antimicrob. Chemother. 43:645449.
7. Hoogkamer, J. F. W., W. H. Hesse, S. Sansano, and W. Zimmerli. 1993. Pharmacodynamic activity of a cephalosporin, Ro 40-6890, in human skin blister fluid: antibiotic activity in concert with host defense mechanisms. Antimicrob. Agents Chemother. 37:2622-2627.
8. Johnson, J. H., M. A. Cooper, J. M. Andrews, and R. Wise. 1992. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob. Agents Chemother. 36:2444-2446.
9. Kawakami, K., K. Namba, M. Tanaka, N. Matsuhashi, K. Sato, and M. Takemura. 2000. Antimycobacterial activities of novel levofloxacin analogues. Antimicrob. Agents Chemother. 44:2126-2129.
10. Lober, S., S. Ziege, M. Rau, G. Schreiber, A. Mignot, P. Koeppe, and H. Lode. 1999. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob. Agents Chemother. 43:1067-1071.
11. Naber, C. K., M. Steghafner, M. Kinzig-Schippers, C. Sauber, F. Sörgel, H.-J. Stahlberg, and K. G. Naber. 2001. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob. Agents Chemother. 45:293-297.
12. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Nye, K., Y. G. Shi, J. M. Andrews, J. P. Ashby, and R. Wise. 1989. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J. Antimicrob. Chemother. 24:415-424.
14. Pendland, S. L., K. J. Losnedahl, and C. A. Schriever. 1999. In-vitro activity of gatifloxacin, a novel fluoroquinolone, compared with that of ciprofloxacin against Legionella spp. J. Antimicrob. Chemother. 44:295-297.
15. Perry, C. M., J. A. Barman Balfour, and H. M. Lamb. 1999. Gatifloxacin. Drugs 58:683-696.
16. Roblin, P. M., and M. R. Hammerschlag. 1999. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. J. Antimicrob. Chemother. 44:549-551.
17. Schaumann, R., G. Ackermann, B. Pless, M. C. Claros, and A. C. Rodloff. 1999. In vitro activities of gatifloxacin, two other quinolones, and five non-quinolone antimicrobials against obligately anaerobic bacteria. Antimicrob. Agents Chemother. 43:2783-2786.
18. Tanswell, P., and J. Koup. 1993. TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Int. J. Clin. Pharmacol. Ther. Toxicol. 31:514-520.
19. Trampuz, A., M. Wenk, Z. Rajacic, and W. Zimmerli. 2000. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob. Agents Chemother. 44:1352-1355.
20. Wise, R., J. M. Andrews, J. P. Ashby, and J. Marshall. 1999. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J. Antimicrob. Chemother. 44:701-704.
21. Yamamoto, T., H. Kusajima, M. Hosaka, H. Fukuda, Y. Oomori, and H. Shinoda. 1996. Uptake and intracellular activity of AM-1155 in phagocytic cells. Antimicrob. Agents Chemother. 40:2756-2759.
22. Zimmerli, W., S. Sansano, and B. Wittke. 1996. Pharmacokinetics of cefetamet in plasma and skin blister fluid. Antimicrob. Agents Chemother. 40:102-104.